Translation enhancer element of the human amyloid precursor protein gene
The present invention is directed to a DNA element that enhances the translation of the human amyloid precursor protein (APP) gene. The enhancer may be incorporated into expression vectors to enhance recombinant protein production. In addition, the invention is directed to an assay that utilizes vectors containing the translation enhancer element for the purpose of identifying agents that modulate the expression of the human amyloid precursor protein. These agents will ultimately be used to suppress APP expression in patients with Alzheimer's disease.
1. A method for assaying a test compound for its ability to alter the expression of the human amyloid precursor protein, comprising:
a) preparing a vector for recombinantly expressing a peptide or protein in a eukatyotic cell, wherein said vector comprises:
i) a promoter which is active in said eukaryotic cell;
ii) a translation enhancer element consisting essentially of the nucleotide sequence of SEQ ID NO:1, wherein said element is 3′ to said promoter;
iii) a DNA sequence encoding said peptide or protein, wherein said DNA sequence:
aa) lies 3′ to said translation enhancer element;
bb) is operably linked to said promoter; and
cc) is non-homologous to said translation enhancer element;
b) measuring the expression of said peptide or protein in said vector in the absence of said test compound; and
c) comparing the expression determined in step b) with the expression of said peptide or protein in the presence of said test compound.
2. The method of claim 1 , further comprising transforming a host cell with said vector prior to measuring the expression of said peptide or protein.
3. The method of claim 1 , wherein said test compound comprises a nucleic acid sequence complementary to a region of SEQ ID NO:1 at least 10 base pairs in length.
4. The method of claim 1 , wherein said test compound is an RNA targeting compound.
5. The method of claim 2 , wherein said host cell is an astrocyte or astrocytoma cell.
6. The method of any one of claims 1 - 5 , wherein said assay is carried out in the presence of one or more cytokines.
7. The method of any one of claims 5 , wherein said assay is carried out in the presence of either interleukin-1α or interleukin-1β.
8. The method of any one of claim 1 - 5 , wherein said method includes measuring mRNA levels of said protein or peptide.
9. The method of claim 8 , wherein said assay is carried out in the presence of one or more cytokines.
10. The method of claim 8 , wherein said assay is carried out in the presence of either interleukin-1α or interleukin-1β.